Our manuscript was published in Nature Communications! The CEA-CD3 T-cell bispecific antibody, cibisatamab, with or without atezolizumab - including MSS-CRC: phase 1/1b trials. rdcu.be/dHYSb
Neil H. Segal MD PhD
@segaln
GI oncologist, Memorial Sloan Kettering Cancer Center, focusing on colorectal cancer immunotherapy
53 Following 106 Followers 3 Posts
Latest posts 1